Early Metabolomic and Immunologic Biomarkers as Prognostic Indicators for COVID-19

Area of Science:

• Biochemistry
• Immunology
• Infectious Diseases

Background:

• Coronavirus Disease 2019 (COVID-19) poses a significant global health challenge.
• Identifying reliable prognostic biomarkers is crucial for managing disease severity and patient outcomes.
• Previous research has explored various markers, but a comprehensive understanding of metabolomic and immunologic interactions is still developing.

Purpose of the Study:

• To identify prognostic metabolomic and immunologic biomarkers for Coronavirus Disease 2019 (COVID-19) severity.
• To investigate the association between disease severity and specific metabolites and cytokines.
• To evaluate the predictive value and interrelationships of these biomarkers for patient stratification.

Main Methods:

• Prospective study involving 327 patients in Hong Kong with COVID-19.
• Analysis of metabolomic profiles and cytokine/chemokine levels in relation to disease severity.
• Statistical analysis including correlation assessments and receiver operating characteristic (ROC) curve analysis to determine predictive value (Area Under the Curve - AUC).

Main Results:

• Disease severity significantly impacted the metabolome, with most associated metabolites downregulated in severe cases.
• Ten cytokines/chemokines were strongly associated with severity, all showing upregulation.
• Fourteen metabolites and five cytokines/chemokines demonstrated high predictive value (AUC > 0.8), with specific metabolites showing high sensitivity or specificity for severe disease.
• Significant correlations were observed between multiple pairs of metabolomic and immunologic biomarkers.

Conclusions:

• Metabolomic and immunologic biomarkers interact closely and hold significant prognostic potential for COVID-19.
• These biomarkers can enable effective outcome-based patient stratification.
• The findings contribute to a deeper understanding of COVID-19 pathogenesis and biomarker discovery.